Content

»	Drug Reactions and Interactions
	»	Cytochrome P450 Enzymes
	»	Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)
	»	Acute Generalized Exanthematous Pustulosis (AGEP)
	»	Neutrophilic Eccrine Hidradenitis (NEH)
	»	Anticoagulant-Induced Skin Necrosis
	»	Erythema Multiforme
	»	Stevens–Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN)
»	References

References

1. Adams DR. Adverse drug reactions in the skin. In: Schwarzenberger K, Werchniak AE, Ko CJ, eds. Requisites in Dermatology: General Dermatology. Philadelphia, PA: Elsevier Ltd; 2009:365-388.

2. Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5-dihydrotestosterone in vitro. J Investig Dermatol. 1993;100:660-662.

3. Armstrong AW. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In: Schwarzenberger K, Werchniak AE, Ko CJ, eds. Requisites in Dermatology: General Dermatology. Philadelphia, PA: Elsevier Ltd; 2009:23-28.

4. Badalementi S, Kerdel F. Azathioprine. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:165-179.

5. Braiteh F, Kurzrock R. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol. 2008;26(20):3460-3462.

6. Burgin S, Wolverton SE, Callen JP. Cutaneous drug eruptions. In: Callen JP, Jorizzo JL, eds. Dermatological Signs of Internal Disease. 4th ed. Philadelphia, PA: Elsevier Ltd; 2009:401-410.

7. Callen JP, Camisa C. Antimalarial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:251-268.

8. Callen JP, Kulp-Shorten CL, Wolverton SE. Methotrexate. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:147-164.

9. Del Rosso JQ. Topical chemotherapy for the treatment of skin cancer. In: Rigel DS et al., eds. Cancer of the Skin. Philadelphia, PA: Elsevier Saunders Inc; 2005:619-630.

10. Evans TY, Vander Straten MR, Carrasco DA, Carlton S, Tyring SK. Systemic antiviral agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:85-108.

11. French LE, Prins C. Toxic epidermal necrolysis. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:323-330.

12. Gollnick H. Systemic Therapy. In: Burgdorf WH, Plewig G, Wolff HH, Ladthaler M, eds. Braun-Falco’s Dermatology. 3rd ed. Heidelberg: Springer; 2009:1573-1593.

13. Gordon KB, West DP. Biologic therapy in dermatology. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:928-942.

14. Greaves MW. Antihistamines. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:360-374.

15. Gupta AK. Systemic antifungal agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:55-84.

16. Holzle E. Physical therapy: light, cold, heat. In: Burgdorf WH, Plewig G, Wolff HH, Ladthaler M, eds. Braun-Falco’s Dermatology. 3rd ed. Heidelberg: Springer; 2009:1593-1608.

17. Honigsmann H, Schwarz T. Ultraviolet light therapy. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:2109-2119.

18. Knowles SR, Shear NH. Drug hypersensitivity syndromes. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:872-884.

19. Kuenzli S, Saurat JH. Retinoids. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:1991- 2006.

20. Kufe DW, Pollock RE, Weichselbaum RR, et al. Holland-Frei Cancer Medicine. 6th ed. Hamilton, ON: BC Decker Inc; 2003.

21. Levy SB. Sunscreens. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:632-646.

22. Lipp HP, ed. Anticancer Drug Toxicity: Prevention, Management, and Clinical Pharmacokinetics. New York, NY: Marcel Dekker Inc; 1999:263-270.

23. Malvasi A, Tinelli A, Buia A, DeLuca GF. Possible long-term teratogenic effect of isotretinoin in pregnancy. Eur Rev Med Pharmacol Sci. 2009;13:393-396.

24. Mockenhaupt M. Severe cutaneous adverse reactions. In: Burgdorf WH, Plewig G, Wolff HH, Ladthaler M, eds. Braun-Falco’s Dermatology. 3rd ed. Heidelberg: Springer; 2009:473-484.

25. Nesbitt LT. Glucocorticoids. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:1979- 1986.

26. Nguyen EQ, Wolverton SE. Systemic retinoids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:269-310.

27. Perry MC. The Chemotherapy Source Book. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:148-152.

28. Reed BR. Dermatologic drugs during pregnancy and lactation. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:817-847.

29. Revus J, Valeyrie-Allanore L. Drug reactions. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:333-351.

30. Sadick N. Systemic antibacterial agents. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:28-54.

31. Shapiro LE, Knowles SR, Shear N. Drug-drug interactions. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:2085-2110.

32. Shapiro LE, Shear NH. Drug interactions. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:848-871.

33. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis. Arch Pediatr Adolesc Med. 1998;152:1132-1136.

34. Tope WD, Shaffer JJ. Photodynamic therapy. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:2127-2140.

35. Wolverton SE, Callen JP. Cutaneous drug eruptions. In: Callen JP, Jorizzo JL, Bolognia JL, Piette WW, Zone JJ, eds. Dermatological Signs of Internal Disease. 3rd ed. Philadelphia, PA: Elsevier Science Ltd; 2003:343-351.

36. Wolverton SE, Callen JP. Systemic therapy for cutaneous disease. In: Callen JP, Jorizzo JL, eds. Dermatological Signs of Internal Disease. 4th ed. Philadelphia, PA: Elsevier Inc; 2009:411-414.

37. Wolverton SE. Systemic Corticosteroids. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company; 2001:109-148.

38. Woody CM, Lesher JL. Antimicrobial drugs. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. St. Louis, MO: Mosby Elsevier; 2008:2007-2032.

39. Zelickson BD. Mechanism of action of topical aminolevulinic acid. In: Goldman MP, ed. Photodynamic Therapy. 2nd ed. Philadelphia, PA: Saunders Elsevier; 2008:1-9.